Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABO-101 Gene Therapy for MPS IIIB
NCT03315182Phase 2Terminated
- Sponsor
- Abeona Therapeutics Inc.
- Start
- Oct 2017
- Primary completion
- Apr 2022
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of ABO-101 in mucopolysaccharidosis type IIIB, sponsored by Abeona Therapeutics Inc.. Started Oct 2017; status: terminated.
02
Drugs
ABO-101
03
Conditions
mucopolysaccharidosis type IIIB
Beyond the preview
Go deeper on NCT03315182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03315182.